ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/07/23
ADC Therapeutics to Participate in the Jefferies London Healthcare ConferenceGlobeNewsWire • 11/06/23
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual MeetingGlobeNewsWire • 11/02/23
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 10/31/23
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023GlobeNewsWire • 10/24/23
Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSOGlobeNewsWire • 10/04/23
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)GlobeNewsWire • 08/30/23
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/08/23
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023GlobeNewsWire • 08/01/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTPRNewsWire • 07/25/23
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaGlobeNewsWire • 07/24/23
ADC Therapeutics SA (ADCT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 07/14/23
After Plunging -34.06% in 4 Weeks, Here's Why the Trend Might Reverse for ADC Therapeutics SA (ADCT)Zacks Investment Research • 07/13/23
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL PatientsGlobeNewsWire • 07/11/23
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCLGlobeNewsWire • 06/09/23
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid CongressBusiness Wire • 05/11/23
ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceBusiness Wire • 05/10/23
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy UpdateBusiness Wire • 05/09/23